×
About 324,283 results

Highlights in Early Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting
https://www.mdedge.com/hematology-oncology/article/255784/highlights-early-breast-cancer-2022-american-society-clinical
Ann H. Partridge, MD, MPH

Jun 29th, 2022 - Dr Ann Partridge from the Dana-Farber Cancer Institute in Boston, Massachusetts, highlights important new data in early breast cancer presented at American Society of Clinical Oncology (ASCO) 2022. Dr Partridge begins with promising results from the NeoSTAR study, which looked at the use of the novel antibody-drug conjugate (ADC) sacituzumab govitecan in the neoadjuvant setting.

Key Abstracts in Metastatic Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting
https://www.mdedge.com/hematology-oncology/article/255775/key-abstracts-metastatic-breast-cancer-2022-american-society
Harold J. Burstein, MD, PhD

Jun 29th, 2022 - Dr Harold J. Burstein, from the Dana-Farber Cancer Institute in Boston, Massachusetts, reports on important abstracts in the management of metastatic breast cancer from the 2022 American Society of Clinical Oncology (ASCO) annual meeting.

Study finds higher risk of skin cancer after childhood organ transplant
https://www.mdedge.com/dermatology/article/255839/nonmelanoma-skin-cancer/study-finds-higher-risk-skin-cancer-after
Christine Kilgore

Jun 28th, 2022 - A large study showing an increased risk of keratinocyte carcinoma (KC) in children who receive a solid-organ transplant highlights the need for early education about risk reduction and more research to determine optimal timing for screening, say an investigator and two dermatologists with expertise in transplant-related skin issues. The increased incidence of KC in pediatric transplant recipien.

‘Superior’ CLL regimen cuts chemo in half
https://www.mdedge.com/hematology-oncology/article/255835/cll/superior-cll-regimen-cuts-chemo-half
Nancy A. Melville

Jun 28th, 2022 - VIENNA – Ibrutinib and obinutuzumab combined with a three-cycle regimen of chemotherapy as a first-line treatment for fit patients with chronic lymphocytic leukemia (CLL) shows progression-free and overall survival rates that are comparable, if not higher, than those commonly reported with six-cycle regimens, new research shows. “Overall, our data suggests that [the chemoimmunotherapy] regimen.

Good chemo vs. bad chemo: When too much is a bad thing
https://www.mdedge.com/hematology-oncology/article/255824/renal-cell-carcinoma/good-chemo-vs-bad-chemo-when-too-much-bad
Randy Dotinga

Jun 28th, 2022 - A new study finds that mortality is significantly higher among patients with advanced solid tumors who are admitted to the hospital for chemotherapy treatment. The findings – released in a poster session at the annual meeting of the American Society of Clinical Oncology – found that patients with solid tumors were more likely to be treated for nonurgent indications, not be referred to palliativ.

My picks for best of ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255805/asco-lung-cancer/my-picks-best-asco-2022
David H. Henry, MD

Jun 28th, 2022 - CHICAGO – The American Society of Clinical Oncology recently wrapped its annual meeting in Chicago. Many of us attended virtually, or in person, and were wowed by some of the abstracts and their implications for our patients – some practice changing.

Melanoma incidence is up, but death rates are down
https://www.mdedge.com/hematology-oncology/article/255799/melanoma/melanoma-incidence-death-rates-are-down
Jim Kling

Jun 28th, 2022 - CHICAGO – Mortality rates from melanoma have fallen in recent years, likely due to the introduction of checkpoint inhibitors, according to a new analysis of the National Cancer Institute SEER database between 1975 and 2019. “This is very encouraging data and represents the real-world effectiveness of these therapies.

Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255791/asco-lung-cancer/highlights-early-stage-non-small-cell-lung
Howard (Jack) West, MD

Jun 28th, 2022 - Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California. He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated wi.

Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255791/conference-recap/highlights-early-stage-non-small-cell-lung
Howard (Jack) West, MD

Jun 28th, 2022 - Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California. He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated wi.

Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
https://www.mdedge.com/hematology-oncology/article/255779/lung-cancer/adjuvant-vs-neoadjuvant-what-has-asco-2022-taught-us
Joan H. Schiller, MD

Jun 27th, 2022 - We’ve still got some work to do before we can say with authority whether concurrent neoadjuvant chemotherapy and immunotherapy is better than concurrent adjuvant chemotherapy with immunotherapy for non–small cell lung cancer (NSCLC). While there has been some notable progress in this area, we need phase 3 trials that compare the two therapeutic approaches.

Fast Five Quiz: Advanced and Metastatic Prostate Cancer Presentation and Diagnosis
https://www.medscape.com/viewarticle/921119

Jun 27th, 2022 - Despite improvements in detection and treatment, prostate cancer remains a significant cause of morbidity and mortality worldwide, and its incidence is increasing. Globally, over 1.4 million cases of prostate cancer were diagnosed in 2020. Although prostate cancer is often asymptomatic in its early stages, symptoms may arise as the disease progresses. Are you familiar with key aspects of the pr...

Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment
https://www.medscape.com/viewarticle/921254

Jun 27th, 2022 - The incidence of metastatic hormone-sensitive prostate cancer (mHSPC) has significantly increased in recent years, in part due to advancements in imaging technology. Men with metastatic prostate cancer who have not received prior treatment with androgen deprivation therapy (ADT) or who are still sensitive to ADT and do not have castration-resistant cancer are defined as having mHSPC, a lethal d...

Rhabdomyosarcoma Outcomes in Adolescents and Young Adults Worse Than in Children
https://www.medscape.com/viewarticle/976148

Jun 27th, 2022 - NEW YORK (Reuters Health) - New data from rhabdomyosarcoma patients confirm poorer outcomes in adolescents and young adults compared with those in children, despite similar treatment, suggesting that a "tailored and intensive" treatment strategy might be warranted in adolescents and young adults, researchers say. While rare, rhabdomyosarcoma is the most common soft-tissue sarcoma in children an...

ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer
https://www.medscape.com/viewarticle/976182

Jun 27th, 2022 - Tracy L. Rose, MD, MPH, shares the immediate and direct impact of the long-term follow-up data from the JAVELIN Bladder 100 trial, an avelumab maintenance study in patients with advanced urothelial carcinoma, which was part of a poster session at the 2022 ASCO annual meeting. The results of the 38-month follow-up data showed prolonged overall survival in patients using first-line avelumab maint...

When Do Cancer Cases Become a Cancer Cluster?
https://www.medscape.com/viewarticle/976247

Jun 27th, 2022 - In mid-April, news outlets began reporting a possible cancer cluster linked to a high school in New Jersey. More than 100 former students and staff had been diagnosed with brain tumors over a 30-year period, leaving some local residents calling for an investigation. Just weeks later, another cancer cluster warning hit the news. A former Philadelphia Phillies baseball pitcher had died of brain c...

Better Breast Support Lessens ACL Risk in Female Athletes
https://www.medscape.com/viewarticle/976266

Jun 27th, 2022 - SAN DIEGO — Greater breast support was associated with reduction in impact factors contributing to traumatic knee injuries including ACL rupture, based on data from 14 female college athletes. "We know that female athletes have a higher risk of ACL injury compared to males in the same sport, with the highest risk between ages 15 and 18," Hailey Fong, MS, a PhD student at the University of Memph...

Fatty Liver Disease Drives Rise in Liver Cancer Deaths
https://www.medscape.com/viewarticle/976213

Jun 27th, 2022 - LONDON ― Around the world, nonalcoholic fatty liver disease (NAFLD) has driven an increase in deaths from liver cancer over the past decade, overtaking alcoholic liver disease, hepatitis B, and hepatitis C, according to an analysis of the Global Burden of Disease Study 2019. A global rise in liver cancer deaths and chronic liver disease reflects changes in underlying health patterns, said Zobai...

Number of US Cancer Survivors Grew to Over 18 Million
https://www.medscape.com/viewarticle/976225

Jun 27th, 2022 - Of more than 18 million Americans who have a history of cancer, two thirds were aged 65 or older as of January 1 of this year, according to a joint report by the American Cancer Society (ACS) and the National Cancer Institute (NCI). This number has increased by more than 1 million since 2019 and will continue to rise. It is predicted that almost 270,000 new cases of prostate cancer will be diag...

Cancer May Increase Risk of Type 2 Diabetes
https://www.medscape.com/viewarticle/976224

Jun 27th, 2022 - A large Danish study has found that cancer increases the risk of new-onset type 2 diabetes, especially certain types of cancer, most notably pancreatic malignancies. "Our study demonstrates that there is an elevated risk of developing diabetes if a person is affected by lung, pancreatic, breast, brain, urinary tract, or uterine cancers," said Lykke Sylow, PhD, associate professor in the Molecul...

Visceral Adiposity, Bone Density Show Significant Linkage
https://www.medscape.com/viewarticle/976232

Jun 27th, 2022 - Researchers published the study covered in this summary on researchsquare.com as a preprint that has not yet been peer reviewed. Key Takeaways The Visceral Adiposity Index (VAI), which reflects fat distribution and visceral fat metabolism, significantly, positively associated with lumbar bone mineral density (BMD), may help in the prediction, early screening, and evaluation of osteoporosis. Why...